<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 106 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page105.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=106">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 106 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 106</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=106"><img src="../thumb/106.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Musculo-Skeletal Agents - 4.1.3                                                 2020-04 / 75
       entirit., URTI, UTI, thrombocytopen., incr./decr.appetite, weight gain,   withdr.meds., no evid.that concom.aspir. will mitigate incr.risk of as-  Contraindications: Known sulphonamide hypersens., sev.hepat./
       psych. disords., CNS effs., paraesthes., blurr. vis., conjunctivit., tinnit.,   soc.ser.CV thromboembol. events, low.recomm.dos.in mod. hepat.  ren.funct.impairm., asthma/ urticar./allerg.-type reacts.precipit.by as-
       vertigo, palpitat., atrial fibrillat., CHF, non-specif.ECG changes, MI,   impairm., safety & effic.of treatm. exceed.12 wks.in osteoarthrit. &   pir.or NSAID’s incl.other COX-2 specific inhibit., est. ischaem heart
       angina, aggrav.hypertens., dysrhythm., tachycard., flush., CVA incid.,   24 wks.in rheumat.arthrit. not est., pts.with compromis.card.funct.&   dis and/or cerebrovasc.dis.& periph. arter.dis., peri-operat.analges.
       TIA’s, hypertens. crisis, bld.Na decr., alt.bld.test results, cough, dyspn.,   other condits. predispos.to/worsen.by fluid retent., clos. monit. pts.  in coron.artery bypass surg., pregn., lactat., not stud.in childr.und. 18
       epistax., bronchosp., GI disturbs.incl. gastrit./ pept.ulc./haemorrh.&   with exist.CHF/hypertens., monit.ren. funct.in pts.with advanc.ren.  yrs., act.pept.ulcerat./GI bleed., IBD, CHF
       fatalit., hepatit., jaund., hepat.fail., skin & subcutan.disords.incl. Stev.   dis., correct. dehydrat. bef.init. ther., monit.anticoag.activ.when init.  Side effects: CV/cerebrovasc./GI events/cutan. reacts. which may
       John.& tox.epiderm.necrolys, musc.cramps/ spasms, musculo-skelet.  ther/ chang. dos., signs for detect.infects.dimin.  be fatal, GI disturbs.incl. duod. ulc./ oesophag.ulcerat.& intestin.per-
       pain/stiffn., proteinur., ren. fail., fatig., flu-like dis., chest pain, elev.   Drug interactions: Antihypertens.eff.of ACE-inhibit. dimin., incr.  forat., poss. fatal ser.skin reacts.incl.exfoliat.dermatit./Stev. Johns./
       ALT/ AST, nephrotox./hepatotox.& pancreatit. report. with NSAID   GI ulcerat.rate with concom. aspir., fluconazole incr.plasma conc.,   tox.epiderm.necros., prurit., alopec., urticar, bullous erupts., allerg.
       use cannot be ruled out.      natriuret. eff.of furosemide & thiazides reduc., due.to inhibit. of   aggravat., angioed., psych. dis.incl.hallucinat., CNS effs., periph.
       Special precautions: Prescrib.decis.to be bas. on indiv.pts.overall   ren.prostaglandin synthes., Li plasma conc.incr., incr.prothromb.  oed., aggrav. hypertens., dysrhythm., hypertens., palpitat., tachycard.,
       risks, poss.predisposit.to CV/ GI events or cutan.reacts.which may be   time with warfar.  CHF, resp.disords., dyspeps., tooth disords., pancreatit., UTI, flu-like
       fatal, pre-exist.signific.ren.funct.impairm./ uncompensat. HF/hyper-  sympts., accident.injury, bld.dyscras., anx., somnol., blurr. vis., tinnit.,
       tens./liv.cirrhos., monit. ren. & card. funct.& discont.if deteriorat.de-  CELECOXIB UNICORN, (Unicorn) Sandoz [P/S]  flush., elev.hepat.enzym., anaphylax., MI, CV thrombot.events, bleed.
                                     Celecoxib
       tect., dehydrat., adeq.hydrat., new onset/recur.CHF, CF hist., L.ventric.  report.with concom. warfar.& similar agents
       dysfunct., hypertens., pre-exist. oed., comprom.card.funct., monit.BP   Indications: Symptom.treatm.of inflamm./pain in osteoarthrit.&   Warnings and special precautions: Insuffic. data to assess CV
                                     rheumat.arthrit., post.dent.surg. pain, mild to mod.post-op/muscu-
       consid.alt. ther. if signif.rise, signfic.CV event risk fact., incr. thrombot.  safety beyond 1 yr contin. treatm., poss.incr.risk of ser.CV thrombot.
       event (MI/stroke) risk incr.with high dos. & long.durat.ther., re-eval.  loskelet.pain/ prim. dysmenorrh., relief S&S.of ankylos.spondylit.  events/ MI & stroke which may be fatal, high.CV event risk with high.
                                     (S3) CAPS, 46/3.1/0702,0703
       treatm.reg., not a substit. for aspir.in CV prophpylax., do not discont.   724014-001: 100 mg, 60, R81,41  dos.& long.treatm.durat., CV risk fact.e.g hypertens./ diab./smok.&
       anti-platelet ther.& consid.such ther.if pt. at risk, no evid.that concom.  724015-001: 200 mg, 30, R81,41  hypercholesterolaem., not a substit.for aspir.for CV prophylax., prior
                                                                                         st
       aspirin mitig. incr. in ser.thrombot.event risk, ischaem.heart dis. hist.,   Dosage: Low.effect.dos.for short.durat. Not stud. in pts.und.18 yrs.  hist of/act.GI dis., elderly/debilitat., discont.ther.at 1  sign of skin
       incr.risk of skin reacts.in pres.of allergy hist., discont.at 1  signs of   Osteoarthrit: Recomm.dly.dos: 200 mg as sngl. dos./ 2 div.dos.   rash/mucos.les./other hypersens. signs., avoid use until further info
                               st
       skin rash/mucos. les./any other hypersens.sign, mild to mod.hepat.   Dos.up to 400 mg/day have been stud.  avail.in pts.in whom attacks of asthma, urticar./ac.rhinit.have been
       insuffic., elderly, risk of GI complicat.with NSAID’s, other concom.  Rheumatoid arthrit: Recomm.dly.dos: 100- 200 mg 2x/day.  precipitat.by aspir./NSAID’s, pts.known/ suspect. to be poor CYP2C9
       NSAID’s/ aspirin, prior GI dis. hist., concom.acetylsalic.acid even at   Pain post dent.surg: Recomm.dos: 100-200 mg up to max.dly.  metabolis., low. recomm.dos.in pts.rec.the CYP2C9 inhibit. flucona-
       low dos. incr. GI advers. eff. risk, monit.where S&S of liv. dis. develop   dos.of 400 mg. Dos.interv.not less than 4 hrs.  zole, monit.concom.Li/ withdr. meds., no evid.that concom.aspir.will
       & discont.if LFT persist.abnorm., may mask.sympts.of inflam./infect.,   Mild to mod post-op pain: Recomm.dos: 200 mg dly. Some pts.  mitigate incr.risk of assoc.ser.CV thromboembol. events, init.treatm.
       std.INR value monit.in pts.receiv.warfar., monit. methotrex. relat.toxic.  may benef.from addit. 200 mg dos.  at low.recomm.dos.in elderly with body weight &lt;50 kg, low.recomm.
       at dos.great.than 90 mg dly., consid.rifampic.interact., avoid concom.  Mild to mod musculoskelet.pain: Recomm. dos: 200 mg 2x/day.  dos.in mod.hepat.impairm., safety & effic.of treatm.exceed.12 wks.
       aspir dos. above those for CV prophylax., incr.EE & conjug. oestrog.  Mild to mod prim.dysmenorrh: Recomm.dos: 400 mg init.  in osteoarthrit.& 24 wks.in rheumat.arthrit.not est., pts.with compro-
       expos. poss. incr.OC & HRT assoc. advers.eff.in women at risk, con-  follow.by addit.200 mg dos.if need.on 1  day thereaft.200 mg 2x/  mis. card.funct.& other condits. predispos. to/worsen.by fluid retent.,
                                                      st
       com.drugs metabol. by human sulfotransferase (eg. oral salbutamol   day on subseq.days.  clos.monit.pts.with exist. CHF/hypertens., monit.ren.funct.in pts.with
       & minoxidil), monit.pt.at high risk of digox. toxic., lact.intol., monit.  Ankylos.spondylit: Recomm.dos: 200 mg dly.as sngl. dos.or   advanc. ren.dis., correct.dehydrat.bef.init.ther., monit. for ren.toxic.esp.
       ren.funct.with concom. ciclospor./tacrolim.  100 mg 2x/day. Some pts.benef.from tot. dly.dos.of 400 mg.  in imp.ren.funct./HF/liv. dysfunct./diuret.ther/ACE-inhibit/angiotens.II
       Drug interactions: Nephrotox.of cyclosporin & tacrolimus poss.  Contraindications: Known sulphonamide hypersens., act.pept.  recept.antagon.& elderly, init.appropr.meas.if organ syst.funct.(ren/
       enchanc., incr.prothromb.time with warfar., AUC decr.with rifampic,   ulcer./gastr.bleed., inflamm. bowel dis., sev.hepat./ren.funct.im-  hepat) deterior.& consid. discont., monit.anticoag.activ.when init.ther/
       methotrex. plasma conc.poss.incr., antihypetens.eff.of ACE inhibit./   pairm., CHF, asthma/ urticar./allerg.-type reacts.precipit.by aspir. or   chang. dos./concom.novel anticoags.eg apixaban/ dabigatran & rivar-
       angiotensin II antagon.& diuret.poss. dimin., in ren.impairm.ren.funct.  NSAID’s incl.other COX-2 specif.inhib., est. ischaem.heart dis.&/or   oxaban, signs for detect.infects. dimin., consid.withdraw.in wom.exper.
       poss.furth. deterior. with concom.ACE inhibit./angiotensin II antagon.,   cerebrovasc.dis.& periph. arter.dis., peri-operat.analges.in coron. ar-  diffic. conceiv./ undergo.investigat.of infertil., monit. pts.with S&S of liv.
       plasma Li lev.poss.incr., steady state AUC of OC ethinyl estradiol &   tery bypass surg., pregn.& women of childbear. potent.unless using   dysfunct./abnorm.LFT, lactose intol.& poss.eff.on diab.glycaem.control,
       HRT conjug. oestrog. incr.with dos.of 120 mg, eff.of furosemide &   effect. contracept., lactat.  Interactions: Concom.drugs known to inhibit CYP2C9 & meds.me-
       thiazide poss.reduc., C max of digox. incr., AUC incr.by ketoconazole   Side effects: Freq: Allerg.aggrav., insomn., CNS effs., dizzin.,   tabol.by P450 CYP2D6, antihypertens. eff.of ACE-inhibit./angiotens.
       (potent CYP3A4 inhibit.).     headache, periph.oed., bronchit., cough., pharyngit., rhinit., sinusit.,   II recept.antagon./diuret.& beta-block.dimin., incr.GI ulcerat.rate with
       CELEBREX, Pfizer [P/S]        URTI, GI/tooth disords., rash, prurit., UTI, flu-like sympt., accid.inj.   concom.aspir., fluconazole incr. plasma conc., CYP2C9 induc.(eg ri-
                                                                  fampicin/ carbamazepine & barbit.) reduc.plasma conc., natriuret.
       Celecoxib.                    Less freq: Bld.dyscras., ecchymos., angioed., psych. effs., blurr.vis.,   eff.of furosemide & thiazides reduc.due to inhibit.of ren. prostaglan-
       Indications: Symptom.treatm.of inflamm./pain in osteoarthrit.&   tinnit., hypertens.aggrav., dysrhythm., palpitat., tachycard., flush.,   din synthes., Li plasma conc.incr., monit.for poss.methotrex.-relat.
       rheumat.arthrit., pain post.dent. surg., mild to mod.post-op/mus-  vomit., alopec., urticar. Freq.unknown: CVA, CHF, MI, CV thrombot.   toxic., incr. prothromb.time with warfar., nephrotox.eff.of ciclospor/
       culoskelet.pain / prim.dysmenorrh., relief S&S.of ankylos.spondylit.  events, pancreatit., gastr./duod./ oesophag. ulc., intest.perforat., bull.  tacrolimus poss.incr.,
       (S3) CAPS, 33/3.1/0332, 0333.  erupt., elev.hepat.enzym.   See also MDR page 684.
       862444-012: 100 mg, 60, R86,55  Warnings and special precautions: May predispos. to CV/
       862452-008: 200 mg, 10, R28,85  cerebrovasc./GI events/cutan. reacts. poss.fatal, safety & effic.in   EXINEF MSD [P/S]
       862452-007: 200 mg, 30, R86,55  treatm.exceed. 12 wks.in osteoarthrit./24 wks.in rheumat.arthrit.   Etoricoxib.
       Dosage: Low.effect.dos.for short.durat.  not est., poss.incr.risk of ser.CV thrombot.events/ MI/ stroke which   Indications: Symptomat.relief of osteoarthrit.& rheumat.arthrit.,
       Osteoarthrit: Recomm.dly.dos: 200 mg as sngl. dos. / 2 div.dos. Dos.  poss.fatal, insuff.data assess.CV safety beyond 1 yr contin.treatm.,   ac.gouty arthrit., ankylos. spondylit., ac.pain.for max.8 days, prim.
       up to 400 mg/day have been stud.  high.CV event risk with high.dos.& long.treatm.durat., CV risk fact.   dysmenorrh., mod.to sev.ac.dent.surg.post-op pain.
       Rheumatoid arthrit: Recomm.dly.dos: 100/ 200 mg 2x/day.  e.g hypertens./diab./smok.& hypercholesterolaem., not a substit.for   (S3) TABS, 44/3.1/0899, 0900, 0901
       Pain post dent.surg: Recomm.dos: 100-200 mg up to max.dly.dos.  aspir.for CV prophylax., prior hist of/act.GI dis., elderly/ debilitat., dis-  723366-001 60 mg, 28, R250,36
                                          st
       of 400 mg. Dos.interv.not less than 4 hrs.  cont.ther.at 1  sign of skin rash/ mucos. les./other hypersens.signs.,   723367-001 90 mg, 28, R252,69
       Mild to mod post-op pain: Recomm.dos: 200 mg dly. Some pts.  compromis. card. funct.& other condits.predispos.to/worsen. by fluid   723368-001 120 mg, 7, R75,73
       may benef.from addit.200 mg dos.  retent., monit.exist.CHF/hypertens., ren. funct. monit. in advanc.ren.  723368-002 120 mg, 28, R302,77
       Mild to mod musculoskelet.pain: Recomm.dos: 200 mg 2x/day.  dis., monit.S&S of liv.dysfunct./abnorm.LFT, dehydrat.correct.bef.   Dosage:.Short.durat.& low.effect.dos. Recomm. dos. are max.dos.
       Mild to mod prim.dysmenorrh.pain: Recomm. dos: 400 mg init.  init. ther., signs for detect.infects.dimin., anaphylact. reacts., monit.  Osteoarthrit: Recomm.dos: 30 mg or 60 mg once dly.
                                     anticoag.activ.when init.ther./chang. dos., lact.intol., diab.mellit.,
       follow.by addit.200 mg dos.if need. on 1  day thereaft.200 mg 2x/  Rheumat.arthrit: Recomm.dos: 90 mg once dly.
                        st
       day on subseq. days.          concom.drugs known to inhib.CYP2C9 & meds.metabol.by CYP2D6,   Ankylos.spondylit: Recomm.dos: 90 mg once dly.
                                     pts. known/ susp.to be poor CYP2C9 metabolis., concom. Li, excret.
       Ankylos.spondylit: Recomm.dos: 200 mg dly.as sngl.dos.or 100 mg   Ac.pain: Recomm.dos: 90 or 120 mg once dly.for ac.symptomat.
       2x/day. Some pts.benef.from tot. dly.dos.of 400 mg.  in breast milk, consid.withdr.in women exper.diffic. conceiv./underg.  per.& limit.to max.8 days.
                                     infertil. investigat., no evid.that concom.aspir.dimin. incr. risk of as-
       Contraindications: Known sulphonamide hypersens., sev.hepat./  Ac.gouty arthrit: Recomm.dos: 120 mg once dly. for ac.symptomat.
       ren.funct.impairm., asthma/ urticar./allerg.-type reacts.precipit.by as-  soc.ser.CV thromboembol.events.  per.& limit.to 8 days
                                     Interactions: Antihypertens.eff.of ACE-inhibit. dimin., incr.GI ulcer-
       pir.or NSAID’s incl.other COX-2 specific inhibit., est. ischaem heart   Prim.dysmenorrh: Recomm.dos: 120 mg once dly. for ac.symptomat.
       dis and/or cerebrovasc.dis.& periph. arter.dis., peri-operat.analges.in   at.rate with concom.aspir., fluconazole incr. plasma conc., natriuret.  per.& limit.to 8 days
                                     eff.of furosemide & thiazid.reduc.due.to inhibit.of ren. prostagland.
       coron.artery bypass surg., pregn., lactat., not stud.in childr.und. 18 yrs.  synthes., incr.prothromb.time with warfar.  Post-op dent.pain: Recomm.dos: 90 mg once dly.
       Side effects: CV/cerebrovasc./GI events/cutan. reacts.which may   Contraindications: Act.pept.ulcerat./GI bleed., sev. hepat.dys-
       be fatal, GI disturbs.incl. haemorragh. duod./oesophag.ulcerat.& in-  COXLEON, Sandoz [P/S] &  funct., est.creatinine clear.&lt;30 ml/ min., S&S’s of aspirin/other
       testin. perforat., poss.fatal ser.skin reacts.incl.exfoliat. dermatit./Stev.   Celecoxib.  NSAID’s cross-sens., uncontrol. hypertens., pregn.& lactat., childr./
       Johns./tox.epiderm.necros., prurit., alopec., urticar, bullous erupts.,   Indications: Symptom.treatm.of inflamm./pain in osteoarthrit.&   adolesc. und.16 ys., inflamm.bowel dis., CHF (NYHA II- IV), est.is-
       allerg.aggravat., angioed., psych.dis.incl.hallucinat., CNS effs., periph.   rheumat.arthrit., pain post.dent. surg., mild to mod.post-op/mus-  chaem.heart dis.and/or cerebrovasc. & periph.arter.dis., peri-op.
       oed., aggrav.hypertens., arrhythm., hypertens., palpitat., tachycard.,   culoskelet.pain / prim.dysmenorrh., relief S&S.of ankylos.spondylit.  pain in coron. artery bypass graft surg.setting., not recom. in women
       CHF, resp. disords., dyspeps., tooth disords., pancreatit., UTI, flu-like   (S3) CAPS, 46/3.1/0704.702, 0705.703  attempt.to conceive.
       sympts., accident.injury, bld.dyscras., anx., somnol., blurr.vis., tin-  723329-001: 100 mg, 60, R81,42  Side effects: Fluid retent., oed., hypertens.which may be more
       nit., flush., elev.hepat. enzym., anaphylax., ageusia., anosm., asept.   723330-001: 200 mg, 30, R81,42  freq.& more sev.partic.at high dos., poss. fatal ser.skin reacts., ser.
       meningit., vasculit., hepatit., liv.fail., ac.ren.fail., interstit.nephrit.,   Dosage: Low.effect.dos.for short.durat.  hypersens.reacts. incl. anaphylax.& angioed., alveolar osteit., gastro-
       photosens. reacts., MI, menstr. disords., bleed.report.with concom.  Osteoarthrit: Recomm.dly.dos: 200 mg as sngl. dos. /2 div.dos. Dos.  entirit., URTI, UTI, thrombocytopen., incr./ decr. appetite, weight gain,
       warfar.& similar agents       up to 400 mg/day have been stud.  psych.disords., CNS effs., paraesthes., blurr.vis., conjunctivit., tinnit.,
       Warnings and special precautions: Insuffic. data to assess CV   Rheumatoid arthrit: Recomm.dly.dos: 100- 200 mg 2x/day.  vertigo, palpitat., atrial fibrillat., CHF, non-specif. ECG changes, MI,
       safety beyond 1 yr contin. treatm., poss.incr.risk of ser.CV thrombot.  Pain post dent.surg: Recomm.dos: 100-200 mg up to max.dly.dos.  angina, aggrav.hypertens., dysrhythm., tachycard., flush., CVA incid.,
       events/ MI & stroke which may be fatal, high.CV event risk with high.  of 400 mg. Dos.interv.not less than 4 hrs.  TIA’s, hypertens. crisis, bld.Na decr., alt.bld.test results, cough, dyspn.,
       dos.& long.treatm.durat., CV risk fact.e.g hypertens./ diab./smok.&   Mild to mod post-op pain: Recomm.dos: 200 mg dly. Some pts.  epistax., bronchosp., GI disturbs. incl. gastrit./pept.ulc./haemorrh.&
       hypercholesterolaem., not a substit.for aspir.for CV prophylax., prior   may benef.from addit.200 mg dos.  fatalit., hepatit., jaund., hepat.fail., skin & subcutan.disords.incl. Stev.
       hist of/act.GI dis., elderly/ debilitat., discont.ther.at 1  sign of skin   Mild to mod musculoskelet.pain: Recomm.dos: 200 mg 2x/day.  John.& tox. epiderm.necrolys, musc.cramps/ spasms, musculo-skelet.
                             st
       rash/mucos.les./other hypersens. signs., avoid use until further info   Mild to mod prim.dysmenorrh.pain: Recomm. dos: 400 mg init.  pain/stiffn., proteinur., ren.f ail., fatig., flu-like dis., chest pain, elev.
                                                      st
       avail.in pts.in whom attacks of asthma, urticar./ac.rhinit.have been   follow.by addit.200 mg dos.if need. on 1  day thereaft.200 mg 2x/  ALT/ AST, nephrotox./hepatotox.& pancreatit.report. with NSAID
       precipitat.by aspir./NSAID’s, concom.drugs known to inhibit CYP2C9   day on subseq. days.  use cannot be ruled out.
       & meds.metabol.by P450 CYP2D6, low. recomm. dos.in pts.rec.the   Ankylos.spondylit: Recomm.dos: 200 mg dly.as sngl.dos.or 100 mg   Warnings and special precautions: Prescrib. decis. to be bas.
       CYP2C9 inhibit. fluconazole, monit.pts.on Li treatm.when admin./   2x/day. Some pts.benef.from tot. dly.dos.of 400 mg.  on indiv.pts.overall risks, poss. predisposit. to CV/GI events or cu-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page105.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page101.html">101</a>&nbsp;&nbsp;&nbsp;<a href="page102.html">102</a>&nbsp;&nbsp;&nbsp;<a href="page103.html">103</a>&nbsp;&nbsp;&nbsp;<a href="page104.html">104</a>&nbsp;&nbsp;&nbsp;<a href="page105.html">105</a>&nbsp;&nbsp;&nbsp;<a href="page106.html">106</a>&nbsp;&nbsp;&nbsp;<a href="page107.html">107</a>&nbsp;&nbsp;&nbsp;<a href="page108.html">108</a>&nbsp;&nbsp;&nbsp;<a href="page109.html">109</a>&nbsp;&nbsp;&nbsp;<a href="page110.html">110</a>&nbsp;&nbsp;&nbsp;<a href="page111.html">111</a>
             </td>
             <td width="35%"><a href="page107.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page107.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
